Investor Relations April 21, 2025 Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices Read More
Investor Relations April 14, 2025 Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders Read More
Investor Relations April 2, 2025 Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial Read More
Investor Relations March 26, 2025 Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 Read More
Investor Relations March 3, 2025 Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders Read More
Investor Relations February 28, 2025 Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval Read More
